根治性前列腺切除术后早期生化复发中68Ga-PSMA-11-PET/CT的观察者间变异性、检出率与病灶模式
该研究分析了116例根治性前列腺切除术后PSA≤0.6 ng/ml的生化复发患者,由两名核医学医师盲法判读68Ga-PSMA-11-PET/CT。总体检出率为50%(R1/R2分别为49%/51%),观察者间一致性Cohen Kappa为0.74。作者认为PSMA-PET/CT在该患者群体中是用于治疗规划的稳健诊断方法。
要点
- PSA 0-0.2 ng/ml组检出率为24%/27%,0.21-0.3 ng/ml组为57%/57%,0.31-0.6 ng/ml组为65%/68%。
- 局部复发是最常见的病灶表现,其次为淋巴和骨转移。
- 局部、淋巴和骨部位的观察者间一致性Kappa分别为0.76、0.73和0.58。
核心结论
- 在根治性前列腺切除术后早期生化复发的高度同质患者群体中,68Ga-PSMA-11-PET/CT检出率为50%,与文献一致,即使在PSA<0.21 ng/ml的患者中也有临床相关发现。
- 观察者间变异性低,尤其是局部复发和淋巴结评估方面。
- 作者认为PSMA-PET/CT是该患者群体中用于治疗规划的稳健诊断方法。
研究设计与样本
- 回顾性分析116例根治性前列腺切除术后、PSA水平≤0.6 ng/ml且未接受ADT或放疗的患者的68Ga-PSMA-11-PET/CT。
- 由两名核医学医师(R1和R2)盲法判读图像,采用5分制对局部复发、淋巴结、骨病灶和其他发现进行评分(1:肯定良性,2:可能良性,3:不确定,4:可能恶性,5:肯定恶性)。
- 对于分类差异≥2个类别和/或可能导致进一步患者管理差异的发现,由第三名判读者(R3)进行共识判读。
- 将分类系统归为良性(1+2)、不确定(3)和恶性(4+5)后,采用Cohen Kappa分析测量观察者间一致性。
- 分析被评定为阳性(4+5)的患者挽救治疗后的PSA水平时间进程。
主要发现
- 总体检出率(类别4和5)为50%(R1/R2分别为49%/51%)。
- PSA亚组0-0.2 ng/ml、0.21-0.3 ng/ml和0.31-0.6 ng/ml的检出率分别为24%/27%、57%/57%和65%/68%。
- 局部复发是最常见的病灶表现,其次为淋巴和骨转移。
- R1与R2之间的总体Cohen Kappa一致性为0.74;局部、淋巴和骨部位的一致性分别为0.76、0.73和0.58。
- PSMA PET/CT阳性患者挽救治疗后PSA水平下降者占75%(27/36),升高者占25%(9/36);影像提示仅局部肿瘤复发者中PSA下降更常见(86%,18/21),转移性疾病患者中亦观察到67%(10/15)的PSA下降。
关键数值与推荐
- 5分制评分:1分肯定良性,2分可能良性,3分不确定,4分可能恶性,5分肯定恶性。
- 观察者间一致性分析将评分归为良性(1+2)、不确定(3)和恶性(4+5)。
- 分类差异≥2个类别和/或可能导致进一步患者管理差异时进行第三判读者共识判读。
临床怎么用
- 作者认为PSMA-PET/CT在该患者群体中用于治疗规划是稳健的诊断方法。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68Ga-PSMA-11-PET/CT is increasingly used in early-stage biochemical recurrence of prostate cancer to detect potential lesions for an individualized radiotherapy concept. However, subtle findings especially concerning small local recurrences can still be challenging to interpret and are prone to variability between different readers. Thus, we analyzed interobserver variability, detection rate, and lesion patterns systematically in a homogeneous patient population with low-level biochemical recurrence. METHODS: We analyzed 68Ga-PSMA-11-PET/CTs in 116 patients with status post-prostatectomy and PSA levels up to 0.6 ng/ml. None of them received ADT or radiotherapy beforehand. Images were interpreted and blinded by two nuclear medicine physicians (R1 and R2). Findings were rated using a 5-point scale concerning local recurrence, lymph nodes, bone lesions, and other findings (1: definitely benign, 2: probably benign, 3: equivocal, 4: probably malignant, 5: definitely malignant). In findings with substantial discrepancies of 2 or more categories and/or potentially leading to differences in further patient management, a consensus reading was done with a third reader (R3). Interobserver agreement was measured by Cohens Kappa analysis after sub-categorizing our classification system to benign (1 + 2), equivocal (3), and malignant (4 + 5). Time course of PSA levels after salvage treatment of patients rated as positive (4 + 5) was analyzed. RESULTS: The overall detection rate (categories 4 and 5) was 50% (R1/R2, 49%/51%) and in the PSA subgroups 0-0.2 ng/ml, 0.21-0.3 ng/ml, and 0.31-0.6 ng/ml 24%/27%, 57%/57%, and 65%/68%, respectively. Local recurrence was the most common lesion manifestation followed by lymphatic and bone metastases. The overall agreement in the Cohens Kappa analysis was 0.74 between R1 and R2. For local, lymphatic, and bone sites, the agreement was 0.76, 0.73, and 0.58, respectively. PSA levels of PSMA PET/CT-positive patients after salvage treatment decreased in 75% (27/36) and increased in 25% (9/36). A decrease of PSA, although more frequent in patients with imaging suggesting only local tumor recurrence (86%, 18/21), was also observed in 67% (10/15) of patients with findings of metastatic disease. CONCLUSIONS: In a highly homogeneous group of prostate cancer patients with early-stage biochemical recurrence after radical prostatectomy, we could show that 68Ga-PSMA-11-PET/CT has a good detection rate of 50% which is in accordance with literature, with clinically relevant findings even in patients with PSA < 0.21 ng/ml. The interobserver variability is low, particularly concerning assessment of local recurrences and lymph nodes. Therefore, PSMA-PET/CT is a robust diagnostic modality in this patient group for therapy planning.
引用
- Miksch J, Bottke D, Krohn T, et al. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32157427. doi:10.1007/s00259-020-04718-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。